Event Type
Disclosure
Voluntary
Variant
8-K
and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabiliti
Other Events. The Company submitted applications to the FDA for clearance for each of its rapid molecular self-test for CT/NG and its Colli-Pee at-home urine co
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of OraSure Technologies, Inc., dated January 5, 2026 104 Cover Pag